Know Cancer

or
forgot password


Phase 2
61 Years
75 Years
Not Enrolling
Both
Hodgkin´s Lymphoma

Thank you

Trial Information


Inclusion Criteria:



- Hodgkin´s lymphoma (histologically proven)

- CS (PS) I and II with one of the risk factors a-d

1. bulky mediastinal mass (> 1/3 maximum transverse thorax diameter)

2. extranodal involvement

3. ESR > 50 (A), > 30 (B-symptoms)

4. 3 or more lymph node areas involved

- CS (PS) III and IV

- Written informed consent

Exclusion Criteria:

- Leukocytes <3000/microl

- Platelets <100000/microl

- Hodgkin´s Disease as "composite lymphoma"

- Activity index (WHO) < grade 2

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Andreas Josting, Dr.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Cologne

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

BACOPP-21

NCT ID:

NCT00284271

Start Date:

January 2004

Completion Date:

Related Keywords:

  • Hodgkin´s Lymphoma
  • Hodgkin´s Lymphoma
  • eldery patients
  • primary diagnosis
  • Hodgkin Disease
  • Lymphoma

Name

Location